Budd-Chiari syndrome and TIPS – 21 years’ experience

Česká verzia

Authors: V. Šafka ¹; P. Hůlek ^2,3; A. Krajina ⁴; T. Fejfar ²; P. Ďulíček ⁵; Š. Šembera ²; T. Vaňásek ²; V. Jirkovský ²; J. Žižka ⁴; V. Chovanec ⁴; Miroslav Lojík ⁴ ; J. Raupach ⁴; O. Renc ⁴
Authors place of work: Ústav fyziologie, LF UK, Hradec Králové ¹; II. interní gastroenterologická klinika LF UK a FN Hradec Králové ²; Interní klinika LF OU, Ostrava ³; Radiologická klinika LF UK a FN Hradec Králové ⁴; IV. interní hematologická klinika LF UK a FN Hradec Králové ⁵
Published in the journal: Gastroent Hepatol 2014; 68(2): 116-123
Category: Hepatology: Original Article

Summary

Budd-Chiari syndrome (BCS) often has an acute or fulminant course leading to ischaemia and necrosis of the liver parenchyma as consequence of venostasis. Restitution of blood drainage is then a key measure. In the chronic course, symptoms of portal hypertension are dominant. TIPS as a portosystemic shunt ensures both venous drainage as well as corrected portal hypertension.

Patients and methods:
TIPS has already been available for 21 years in the Czech Republic. Using this method we also treated 52 patients with BCS from thrombosis of hepatic veins. The median age was 37 years (13 to 82 years), 10% were children, 16 patients (31%) were men, 31% procedures were urgent. Myeloproliferative syndrome was the cause in 60%, another thrombophilic disorder was detected in 15%, and in 25% of them the cause was not elucidated. In the first five years, uncovered stents were used, but since 1997 different types of ePTFE covered stents have been available and since 2001 dedicated ePTFE covered stents became the standard.

Results:
13 patients died: three of fulminant liver failure, one of extensive tumorous thrombosis, three of early septic complications, two of liver failure due to later acute shunt occlusion, two of progressions of haemato-oncological disease, one tragically, and one of unknown cause. Two patients later underwent OLTx. In 39 patients the shunt remains patent on anticoagulant therapy and occasional reinterventions, liver functions are stable and no portal hypertension complications occur. We have not noticed significant hepatic encephalopathy. The use of ePTFE covered stents reduced a number of mainly early occlusions. In imaging we often find nodular hyperplasia.

Conclusion:
We consider TIPS an advantageous therapeutic approach in BCS due to thrombosis of the hepatic veins. If the follow-up treatment is rigorous, the TIPS usually ensures sufficient perfusion of the liver and prevents portal hypertension complications, saving most patients from liver transplantation.

Key words:
Budd-Chiari syndrome – portal hypertension – transjugular intrahepatic – portosystemic shunt

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
12. 3. 2014

Accepted:
7. 4. 2014

Zdroje

1. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 2003; 38(4): 793–803.

2. Sebastian S, Tuite D, Crotty P et al. Painful ascites. Gut 2004; 53(9): 1344, 1355.

3. Runyon BA, Montano AA, Akriviadis EA et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117(3): 215–220.

4. Gines P, Cárdenas A, Arroyo V et al. Management of cirrhosis and ascites. N Engl J Med 2004; 350(16): 1646–1654.

5. Vanasek T, Dulicek P, Hulek P et al. Erythrocyte sedimentation rate (ESR) as diagnostic test for Budd-Chiari syndrome? J Hepatol 2001; 34: 64. doi: 10.1016/S0168-8278(01)81094-1.

6. Sembera S, Jirkovský V, Fejfar T et al. Survival of patients after TIPS in the University Hospital Hradec Kralove. Vnitr Lek 2011; 57(12): 1038–1044.

7. Jirkovsky V, Fejfar T, Safka V et al. Influence of the secondary deployment of expanded polytetrafluoroethylene-covered stent grafts on maintenance of transjugular intrahepatic portosystemic shunt patency. J Vasc Interv Radiol 2011; 22(1): 55–60. doi: 10.1016/j.jvir.2010.09.016.

8. Safka V, Hůlek P, Krajina A et al. Budd-Chiari syndrome and TIPS – twelve years' experience. Cas Lek Cesk 2005; 144 (Suppl 3): 38–42.

9. Alvarez-Larrán A, García-Pagán JC, Abraldes JG et al. Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol 2004; 124(3): 329–335.

10. Smalberg JH, Darwish Murad S, Braakman E et al. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006; 91(12): 1712–1713.

11. Patel RK, Lea NC, Heneghan MA et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130(7): 2031–2038.

12. Smalberg JH, Arends LR, Valla DC et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120(25): 4921–4928. doi: 10.1182/blood-2011-09-376517.

13. Bhattacharya M, Yeh BM, Qayyum A et al. Case 81: antiphospholipid antibody syndrome with adrenal hemorrhage and Budd-Chiari syndrome. Radiology 2005; 235(1): 53–55.

14. Nanke Y, Kotake S, Nakanishi Y et al. Budd-Chiari syndrome associated with primary antiphospholipid syndrome. Clin Exp Rheumatol 2002; 20(3): 433.

15. Janssen HL, Meinardi JR, Vleggaar FP et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96(7): 2364–2368.

16. Bhattacharyya M, Makharia G, Kannan M et al. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol 2004; 121(6): 844–847.

17. Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology 2008; 47(4): 1384–1393. doi: 10.1002/hep.22192.

18. D'Amico M, Sammarco P, Pasta L. Thrombophilic Genetic Factors PAI-1, MTHFRC677T, V Leiden 506Q, and Prothrombin 20210A in Noncirrhotic Portal Vein Thrombosis and Budd-Chiari Syndrome in a Caucasian Population. Int J Vasc Med 2013: 717480. doi: 10.1155/2013/717480.

19. Minnema MC, Janssen HL, Niermeijer P et al. Budd-Chiari syndrome: combination of genetic defects and the use of oral contraceptives leading to hypercoagulability. J Hepatol 2000; 33(3): 509–512.

20. Hauser AC, Brichta A, Pabinger-Fasching I et al. Fibrinolytic therapy with rt-PA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome. Ann Hematol 2003; 82(5): 299–302.

21. Titton RL, Coakley FV. Case 51: paroxysmal nocturnal hemoglobinuria with thrombotic Budd-Chiari syndrome and renal cortical hemosiderin. Radiology 2002; 225(1): 67–70.

22. Valla DC. Primary Budd-Chiari syndrome. J Hepatol 2009; 50(1): 195–203. doi: 10.1016/j.jhep.2008.10.007.

23. Darwish Murad S, Valla DC et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39(2): 500–508.

24. Orug T, Soonawalla ZF, Tekin K et al. Role of surgical portosystemic shunts in the era of interventional radiology and liver transplantation. Br J Surg 2004; 91(6): 769–773.

25. Molmenti EP, Segev DL, Arepally A et al. The utility of TIPS in the management of Budd-Chiari syndrome. Ann Surg 2005; 241(6): 978–981.

26. Hefaiedh R, Cheikh M, Marsaoui L et al. The Budd-Chiari syndrome. Tunis Med 2013; 91(6): 376–381.

27. Gur I, Diggs BS, Orloff SL. Surgical portosystemic shunts in the era of TIPS and liver transplantation are still relevant. HPB (Oxford) 2013. doi: 10.1111/hpb.12163.

28. Sharma S, Texeira A, Texeira P et al. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol 2004; 40(1): 172–180.

29. Tan HK, Lim JS, Tan CK et al. MARS therapy in critically ill patients with advanced malignancy: a clinical and technical report. Liver Int 2003; 23 (Suppl 3): 52–60.

30. Garcia-Pagán JC, Heydtmann M, Raffa S et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008; 135(3): 808–815. doi: 10.1053/j.gastro.2008.05.051.

31. Rautou PE, Moucari R, Escolano S et al. Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management. Am J Gastroenterol 2009; 104(5): 1140–1146. doi: 10.1038/ajg.2009.63.

32. Zhang K, Xu H, Zu M et al. Predictive value of five prognostic models for Budd-Chiari syndrome in China. Nan Fang Yi Ke Da Xue Xue Bao 2014; 34(1): 88–91.

33. Hernández-Guerra M, Turnes J, Rubinstein P et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004; 40(5): 1197–1202.

34. Klein AS, Molmenti EP. Surgical treatment of Budd-Chiari syndrome. Liver Transpl 2003; 9(9): 891–896.

35. Attwell A, Ludkowski M, Nash R et al. Treatment of Budd-Chiari syndrome in a liver transplant unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation. Aliment Pharmacol Ther 2004; 20(8): 867–873.

36. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49(5): 1729–1764. doi: 10.1002/hep.22772.

37. Kavanagh PM, Roberts J Gibney R et al. Acute Budd-Chiari syndrome with liver failure: the experience of a policy of initial interventional radiological treatment using transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol 2004; 19(10): 1135–1139.